{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-007044","form_type":"8-K","ticker":"BLGO","cik":"0000880242","company_name":"BIOLARGO, INC.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.895868+00:00","generated_at":"2026-05-15T21:16:10.641548+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M","bullets":["Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.","Net loss of $15.2M vs. $4.3M in prior year; cash balance $3.9M at year end.","Engineering services revenue from third parties grew 98% to $2.0M.","Subsidiary Clyra Medical secured first stocking order for ViaCLYR wound irrigation solution.","PFAS treatment system installed in New Jersey; PFAS breakthrough featured in Chemical Engineering."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-007044","json":"https://secwatch.observer/filing/0001437749-26-007044.json","markdown":"https://secwatch.observer/filing/0001437749-26-007044.md","text":"https://secwatch.observer/filing/0001437749-26-007044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/880242/000143774926007044/0001437749-26-007044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/880242/000143774926007044/blgo20260305_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:16:10.641548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}